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Abstract
Background: Schistosomiasis is one of the most important neglected diseases found in developing countries
and affects 249 million people worldwide. The development of an efficient vaccination strategy is essential for
the control of this disease. Previous work showed partial protection induced by DNA-Sm14 against Schistosoma
mansoni infection, whereas DNA-Hsp65 showed immunostimulatory properties against infectious diseases,
autoimmune diseases, cancer and antifibrotic properties in an egg-induced granuloma model.
Methods: C57BL/6 mice received 4 doses of DNA-Sm14 (100 μg/dose) and DNA-Hsp65 (100 μg/dose), simultaneously
administrated, or DNA-Sm14 alone, once a week, during four weeks. Three groups were included: 1- Control
(no immunization); 2- DNA-Sm14; 3- DNA-Sm14/DNA-Hsp65. Two weeks following last immunization, animals
were challenged subcutaneously with 30 cercariae. Fifteen, 48 and 69 days after infection splenocytes were collected
to evaluate the number of CD8+ memory T cells (CD44highCD62low) using flow cytometry. Forty-eight days after
challenge adult worms were collected by portal veins perfusion and intestines were collected to analyze the intestinal
egg viability. Histological, immunohistochemical and soluble quantification of collagen and α-SMA accumulation were
performed on the liver.
Results: In the current work, we tested a new vaccination strategy using DNA-Sm14 with DNA-Hsp65 to potentiate
the protection against schistosomiasis. Combined vaccination increased the number of CD8+ memory T cells and
decreased egg viability on the intestinal wall of infected mice. In addition, simultaneous vaccination with DNA-Sm14/
DNA-Hsp65 reduced collagen and α-SMA accumulation during the chronic phase of granuloma formation.
Conclusion: Simultaneous vaccination with DNA-Sm14/DNA-Hsp65 showed an immunostimulatory potential and
antifibrotic property that is associated with the reduction of tissue damage on Schistosoma mansoni experimental infection.
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Background
Schistosomiasis is one of the most important neglected
diseases found in developing countries and constitutes a
serious public health problem that is directly related to
poverty and social disadvantage [1,2]. This disease affects
249 million people worldwide [3]. The drugs that are
currently available do not prevent reinfections and are
inefficient against the immature stages of the worm.
Therefore, the development of an efficient vaccination
strategy is an essential component in the control of the
disease [4,5].
Protection as a result of immunization with recom-
binant Sm14, a fatty acid-binding protein, ranged
from 25% to 67% in mice using different approaches
[6-9]. The use of DNA as a vaccine that stimulates
all arms of adaptive immunity, including both cellular
and humoral responses, is one of the most promising
techniques for immunization against various patho-
gens and tumors [10]. DNA vaccines against S. man-
soni were experimentally described against different
epitopes such as Sm-p80 [11,12], Sm23 [13], SmCT-
SOD [14] and a multivalent vaccine [15]. In an
attempt to enhance rSm14 protection, the use of the
DNA-Sm14 vaccine co-administered with the plasmid
containing the gene for IL-12 altered the immuno-
logic profile but failed to increase the protection
provided by DNA-Sm14 alone, which was 40% [16].
Given the immunostimulatory and protective poten-
tial of DNA-Sm14 in the prevention against schisto-
somiasis, new strategies that complement and
modulate the immune response generated by DNA-
Sm14 are important to achieve satisfactory protection
levels.
Our group has previously reported the immunostimu-
latory properties of the Mycobacterium leprae 65-kDa
heat-shock protein (DNA-Hsp65), which is protective
against M. tuberculosis [17-19] and effective as an
immunomodulatory agent in several diseases, such as
leishmaniasis [20], paracoccidioidomycosis [21], chromo-
blastomycosis [22], diabetes [23], arthritis [24], allergy
[25] and phase I cancer trials [26,27]. Our group also re-
ported that in a model of S. mansoni egg-induced fibro-
sis, the administration of DNA-Hsp65 reduced fibrotic
processes during granuloma formation and led to a de-
crease in collagen deposition at the injury site [28].
Thus, in the current study, we tested a new vaccination
strategy using DNA-Sm14 and DNA-Hsp65, where
DNA-Sm14 would induce specific immune responses
against S. mansoni and DNA-Hsp65 would potentiate
the immune response in a non-specific manner. This
immunization strategy would achieve optimal levels of
protection and tissue preservation against S. mansoni in-
fection and overcome the difficulties found in DNA-
Sm14 vaccination.
Methods
Animals
C57BL6/6 mice (20-25 g) were obtained from the animal
facilities of Faculdade de Ciências Farmacêuticas de
Ribeirão Preto, Universidade de São Paulo (FCFRP - USP).
All of the experiments were approved and conducted in
accordance with the guidelines of the Animal Care Com-
mittee of the University (Protocol No. 09.1.144.53.3).
Parasites and experimental infection
Schistosoma mansoni LE strain was maintained by rou-
tine passage through Biomphalaria glabrata snails and
BALB/c mice (20-25 g) from the animal facilities of
Faculdade de Medicina de Ribeirão Preto, Universidade
de São Paulo (FMRP - USP). The infected snails were in-
duced to shed cercariae under light exposure in water
for 2 hours. The number of cercariae in suspension was
determined, and the mice were subcutaneously injected
with 30 cercariae/mouse with the help of a sterile syr-
inge and a 22G1 needle (BD Biosciences).
DNA vaccines
The Sm14 gene was isolated from the pMAL-c2/Sm14
construct by digestion with the enzymes Xba I and Sal I
and subcloned into the mammalian expression vector
pCI (Promega Corp., Madison, WI, USA). The pCI/
Sm14 plasmid was used to transform Escherichia coli
DH5α cells, and the clones containing the insert were
selected by resistance to ampicillin. The presence of the
Sm14 insert in the pCI/Sm14 construct was confirmed
by restriction analysis and sequencing as previously de-
scribed [16]. The Hsp65 gene was isolated from M.
leprae and cloned into BamH I – Not I restriction sites
of the pVAX1 vector (Invitrogen Corp., Carlsbad, CA,
EUA). The pVAX1/Hsp65 plasmids were replicated in
DH5α Escherichia coli cells, and the clones containing
the insert were selected by resistance to kanamycin. The
presence of the Hsp65 insert in the pVAX/Hsp65 con-
struct was confirmed by restriction analysis and sequen-
cing [17]. The pCI/Sm14 and pVAX/Hsp54 plasmids were
purified using the Endofree Plasmid Giga kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s proto-
col. The endotoxin levels were determined using a QCL-
1000 Limulus amebocyte lysate kit (Cambrex Company,
Walkersville, MD, USA) and were less than 0.1 endotoxin
units (EU)/μg, as recommended by European and US
Pharmacopoeias. pCI/Sm14 is referred here as DNA-Sm14
and pVAX/Hsp65 is referred to as DNA-Hsp65.
Immunization procedures
C57BL/6 mice received four doses of 100 μg/each of
purified DNA-Sm14 or DNA-Hsp65 in the quadriceps
muscle with an interval of one week between each dose
[15], on days 1, 7, 14 and 21 (100 μg in 100 μL of 50%
Espíndola et al. BMC Infectious Diseases 2014, 14:263 Page 2 of 9
http://www.biomedcentral.com/1471-2334/14/263
sterile buffered sucrose). For the simultaneous adminis-
tration of DNA-Sm14/DNA-Hsp65, mice received four
doses of each plasmid at a final concentration of 2 μg/
μL (100 μg in 50 μL of 50% sterile buffered sucrose) and
administered in different legs. Thirty-six days after the
beginning of immunization, the mice were infected with
30 cercariae of S. mansoni subcutaneously, injected
using a syringe. After 15, 48 or 69 days post infection,
the mice were euthanatized, and the results were ana-
lyzed. A total of eighteen animals per group were used,
and each experiment was performed twice. For each
time point the number of euthanatized mice was differ-
ent, as following: on day 15 after infection, 3 mice per
group; on day 48, 8 mice per group and on day 69, 7
mice per group were euthanatized. For each different
parameter the number of mice is specified in the subtitle
of the figure.
Parasitic burden
Forty-eight days post-infection, the adult worms were
recovered by hepatic and mesenteric perfusion using
previously reported techniques [29] with minor modifi-
cations. The worms were counted under a dissecting
microscope to evaluate the worm burden. The protec-
tion level was calculated by comparing the number of
worms recovered from each experimental group and the
controls using the following formula: P = [(C −V)/C] ×
100, where P is the % protection, C is the mean worm
count in the control animals and V is the mean worm
count in the vaccinated animals. For parasitic burden
evaluation, two independent experiments were performed,
on which 6-7 animals per group were used on Experiment
1, and 7-8 animals per group on Experiment 2.
Intestinal egg viability
Following perfusion to recover the parasites, fragments
of the intestine (terminal ileum) from each animal were
separated and washed in saline solution. The intestines
were opened lengthwise, and the excess mucus was re-
moved. One-centimeter fragments were cut off, partially
dried on absorbent paper and placed between a glass
slide and coverslip. The preparation was inverted and
pressed on a rubber surface padded with filter paper
[30]. The fragments were examined with an optical
microscope (100×), and 200 eggs/mouse were counted
and classified according to the developmental stage as
follows: (i) viable immature eggs (1st to 4th stage), (ii) vi-
able mature eggs or (iii) dead eggs [31]. The percentage
of eggs in each egg stage was calculated.
Immunophenotyping of cells by flow cytometry
After immunization and infection, the spleen memory T
lymphocyte phenotypes were evaluated using flow cy-
tometry. CD4, CD8, CD44 and CD62L expression were
determined by immunostaining with antibodies conju-
gated to different fluorochomes (BD Biosciences, NJ,
USA). Specific rat IgG2a isotype controls were used to
monitor non-specific binding. The stained cells were
washed with FACS buffer (PBS containing 2% fetal bo-
vine serum (FBS) and 1 g/L of NaN3), pelleted by centri-
fugation at 400x g and fixed with PBS containing 1%
(w/v) paraformaldehyde. A total of 30,000 events were
acquired (FACSCanto TM; Becton Dickinson, CA, USA)
using the FACS Diva for data acquisition and analysis.
The data were analyzed using the number of events of
each cell marker. Thirty thousand events per sample
were collected, each sample corresponded to an individ-
ual mouse, and three-color fluorescence-activated cell
analysis was performed. CD8+ CD44hiCD62Llow cells
were analyzed through the expression of CD62L from
CD44hi CD8+ cells gated lymphocyte populations.
Histologic and immunohistochemical analysis
Liver fragments were collected, fixed in 10% formalin and
processed for paraffin embedding for the histological and
immunohistochemical studies. Five-micrometer-thick sec-
tions were cut and stained with HE for histopathological
analysis and Picrosirius red to visualize collagen around
the granulomas. Immunohistochemical staining was per-
formed to analyze the fibrotic marker α-SMA (Abcam). A
minimum of 25 granulomas per group were measured for
the analysis. The surface density of the collagen and
α-SMA fibers in the liver was determined by optical dens-
ity image analysis. The images were captured using a video
camera (Leica® Microsystems, Heebrugg, Switzerland)
coupled to a DMR microscope (Leica®, Microsystems
GmbH, Wetzlar, Germany) and computer. The images
were processed using Leica QWin software (Leica Micro-
systems Image Solutions®, Cambridge, UK). The thresh-
olds for the collagen fibers were established for each slide
after enhancing the contrast until the fibers were easily
identified as red bands. The values are expressed as a per-
centage of the area.
Collagen assay
Liver slices from infected mice were homogenized in a
specific solution (EDTA 1 mM, Indometacin 10 μM and
Protease Inhibitor Cocktail Tablets - 1 tablet/50 mL of
solution). For each 100 mg of tissue, 1 mL of solution
was used and homogenates were obtained after 30 sec-
onds of homogenization, followed for 30 min centrifuga-
tion (1,200x g) and the total volume of supernatants
were collected, which were used for soluble collagen
quantification as described. 1 mL of Sircol-dye was
added to 100 μL of supernatant, and the contents of the
tubes were homogenized for 30 min and centrifuged for
10 min (10,000x g). The pellets were dissolved in 250 μL
of an alkaline reagent. The absorbance was read at
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540 nm. The total soluble collagen was determined using
a standard curve [32] and normalized to the total pro-
tein levels (in milligrams) present in the supernatants of
each sample measured by the Bradford assay as previ-
ously described [33].
Statistical analysis
The data are represented as the mean ± SEM and were
analyzed using GraphPad Prism version 5.0 (GraphPad
Software, San Diego, CA). The comparisons were per-
formed using a one-way analysis of variance with the
Newman-Keuls post-test. Differences were considered
significant if the P value was < 0.05. The experiments
were repeated 2 times with similar results and for each
specific assay we used a representative number of mice
that is specified on the referred subtitle.
Results
The main feature of vaccination is the induction of im-
munogenicity, in which the generation of memory cells
is highly associated with protective immunity against
specific antigens for long periods of time. To determine
the impact of DNA-Sm14 and DNA-Sm14/DNA-Hsp65
on the generation of memory T cells, we assessed the
frequencies of CD4+ and CD8+ memory T lymphocytes
in the spleen of mice infected with S. mansoni. Vaccin-
ation with DNA-Sm14 or DNA-Sm14/DNA-Hsp65 in-
creased the number of CD8+ CD44hiCD62Llow cells 48
and 69 days post infection (Figure 1A). The number of
CD4+ CD44hiCD62Llow cells increased slightly post
combined vaccination (data not shown). Moreover, we
observed that immunization with DNA-Sm14/DNA-
Hsp65 induced the highest ratio of memory CD8+ lym-
phocytes to the total number of CD8+ cells in the spleen
(Figure 1B). However, the ratio of CD4+ cells did not
change (data not shown). Thus, these results indicate
that the combined vaccination induces the differenti-
ation of CD8+ memory T cells but not CD4+ T cells.
The major parameter to be considered in vaccine ef-
fectiveness is directly related to reducing the number of
microorganisms in the host. Thus, we analyzed the ef-
fects of our vaccines on the reduction of parasite burden
and egg viability. Vaccination with DNA-Sm14 alone in-
duced 34.5% and 28.2% of worm reduction in the first
and second sets of experiments, respectively. Simultan-
eous vaccination with DNA-Sm14/DNA-Hsp65 failed to
reduce the worm burden in both experiments (Table 1),
that could be explained by the less potent Th1 differenti-
ation in this group observed by enhanced IgG1/IgG2a
ratio (Additional file 1: Figure S1 and Table S1) com-
pared to DNA-Sm14 and by the decreased IFN-γ release
on bronchoalveolar space (Additional file 1: Figure S2).
Although there was no difference in parasite load, DNA-
Sm14/DNA-Hsp65 increased the amount of dead eggs
in the intestinal tissue by 96.5% compared to the control
group, while DNA-Sm14 only increased the amount of
dead eggs by 60.35% (Figure 2). Thus, the addition of
DNA-Hsp65 to the vaccination strategy decreased egg
viability and possibly reduced the secretion of soluble
egg antigens, which are responsible for the strong granu-
lomatous response observed in the liver and intestine of
mice.
Figure 1 A combined vaccination strategy using DNA-Sm14/DNA-Hsp65 increased the number of CD8+ memory T cells in the spleen
of infected mice. A) The number of CD8+ CD44hiCD62Llow memory T lymphocytes in the spleen of mice without immunization (Control) or
immunized with DNA-Sm14 or DNA-Sm14/DNA-Hsp65 and infected with S. mansoni over time (15, 48 and 105 days after infection). B) The ratio
of CD8+ memory T lymphocytes / total number of CD8+ in the spleen of mice vaccinated with DNA-Sm14 or DNA-Sm14/DNA-Hsp65 and
infected with S. mansoni on days 15 and 48 post infection. After immunization, the mice were infected with 30 cercariae, and the phenotype of
the memory T lymphocytes in the spleen was evaluated using flow cytometry. The results are expressed as the mean ± standard error from 3-5
animals/group and are representative of two experiments. A) *p < 0.05 DNA-Sm14/DNA-Hsp65 48 days vs 15 days; DNA-Sm14 48 days vs 15 days;
#p < 0.05 DNA-Sm14/DNA-Hsp65 69 days vs 48 days; DNA-Sm14 69 days vs 48 days. B) *p < 0.05 DNA-Sm14/DNA-Hsp65 48 days vs Control
group 48 days.
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A kinetic analysis of granuloma-induced fibrosis re-
vealed that activated hepatic stellate cells (HSCs α-SMA+)
and alternatively activated macrophages are the main
extracellular matrix producing cells. Both cell types con-
tribute to fibrotic tissue remodeling and collagen depos-
ition [34]. To test whether our DNA vaccines would
reduce the accumulation of extracellular matrix compo-
nents, we measured α-SMA and collagen deposition
around the granulomas 69 days post infection, which is
considered the chronic phase, as well as the soluble colla-
gen concentration in the liver homogenates. By day 69,
DNA-Sm14/DNA-Hsp65 reduced the accumulation of
collagen around the granulomas compared to immuniza-
tion with DNA-Sm14 alone (Figure 3A). In addition, com-
bined vaccination reduced the formation of α-SMA fibers
(Figure 3B). The enhanced levels of soluble collagen in
control group 69 days post infection were not observed on
mice vaccinated with DNA-Sm14 or with both vaccines,
indicating that vaccination with DNA-Sm14 alone or com-
bined with DNA-Hsp65 decreases the extracellular matrix
machinery, leading to the enhancement of tissue preserva-
tion (Figures 3C and 4).
Discussion
The use of DNA vaccines has been widely studied as a
promising tool against various diseases, including para-
sitic diseases. DNA vaccines not only induce potent cel-
lular and humoral responses but also modulate the
immune system by enhancing immunogenicity. Among
these strategies, the use of delivery systems for DNA,
including polymers, liposomes and nano- or microparti-
cles, or even the use of adjuvants, which may be co-
administered as plasmids that carry immunomodulator
genes such as cytokines or costimulatory molecules, help
to optimize and direct the desired response profile
[35,36]. Strategies using a combination of plasmids ex-
pressing different antigens were successfully tested in
human filariasis; these strategies led to an increase in
immunogenicity and protection [37]. In leishmaniasis,
the combination of antigens increased the number of tar-
geted epitopes by the immune system and had an additive,
perhaps even a synergistic response [38]. Therefore, we
hypothesized that vaccinating with the DNA-Sm14 and
DNA-Hsp65 plasmids would result in an additive modula-
tion of the immune response.
Both vectors used in the present work were already
tested on Schistosomiasis, using distinct protocols by di-
verse groups. pCI was used as a control on S. mansoni
infection and did not induce protection compared to
pCI/Sm14 [16]. On the other hand, pVax, without an en-
coding gene, was evaluated by Frantz et al., 2011, as a
control in a pulmonary granuloma model, and had no
effects at granuloma reduction area neither on the di-
minished expression of Pro-collagen1 and α-SMA after
fibrosis induction. Therefore, the vectors alone had no
influence on protection against S. mansoni experimental
protocols compared to the vectors carrying the specific
genes, and for these reasons were not used as a control
in our work.
As the generation of memory T cells is the central
event for a successful vaccination, we first investigated
Table 1 Protection level induced by immunization with DNA-Sm14 or DNA-Sm14/DNA-Hsp65 48 days post infection
with S. mansoni
Experiment Groups Worm Burden (mean) ± SEM n Protection
1 Control 19.86 1.405 7 -
1 DNA-Sm14 13.00* 1.024 7 34.5%a
1 DNA-Sm14/DNA-Hsp65 16.83 0.749 6 15.3%a
2 Control 18.29 0.746 7 -
2 DNA-Sm14 13.13* 1.231 8 28.2%a
2 DNA-Sm14/DNA-Hsp65 16.00 1.291 7 12.5%a
*Significant reduction in worm burden recovery compared to control group in each experiment. p < 0.05.
aWorm burden reduction compared to Control group in each experiment.
Figure 2 Simultaneous vaccination with DNA-Sm14/DNA-Hsp65
reduces egg viability. Two weeks after the last immunization, the
mice were infected with 30 cercariae, and the developmental stages
of the eggs were evaluated in the intestinal tissue 48 days post
infection. The intestinal eggs were identified as immature, mature
or dead using the Oogram technique. The results are expressed
as the mean ± standard error from 6-7 animals/group and are
representative of two experiments. *p < 0.05 vs Control group.
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the frequencies of the memory T cells. Surprisingly,
there was no modulation of CD4+ memory T cells with
either of the vaccination strategies, which is in contrast
to the idea that DNA vaccines are able to induce both
subtypes of memory T cells similarly. Thus, the high fre-
quency of memory CD8+ T cells found in mice that re-
ceived DNA-Hsp65 in addition to DNA-Sm14 is in
agreement with reports that Hsp65 protein and DNA
preferentially induce the production of CD8+ T cells
[39,40].
The addition of DNA-Hsp65 to the DNA-Sm14 strat-
egy was not able to enhance or induce similar protection
levels observed with DNA-Sm14 alone. In fact, the loss
of efficacy of combined vaccination was an unexpected
result, even though it has been reported that immuno-
modulatory molecules fail to enhance protection, as
observed in a study where co-administration of DNA-
Sm14 and IL-12 failed to protect against S. mansoni in-
fection [16]. In our study, the higher levels of CD8+ T cell
activation may explain the low efficacy of the combined
vaccination protocol tested, mainly because CD8+ T cells
are essential for the eradication of intracellular pathogens,
while in the case of extracellular parasites, such as S. man-
soni, these cells have no cytotoxic function.
As the major cause of death in schistosomiasis is the
chronic pathology caused by egg deposition, the devel-
opment of vaccines that interfere with female fecundity
or egg viability is an important parameter to be evalu-
ated. In this study, we did not observe differences in egg
deposition on the intestinal wall among the groups.
However, we observed that DNA-Sm14/DNA-Hsp65
enhanced the number of dead eggs compared to DNA-
Sm14 alone. This reduction in egg viability is in agree-
ment with previous studies that used Sm14 peptides for
the vaccinations [41]. Thus, although the combination of
vaccines was unable to protect against infection, vaccin-
ation may have played a positive role in the pathology
caused by the eggs and the control of disease dissemin-
ation. In this sense, the dead eggs dispensed into the en-
vironment would be unable to continue the life cycle of
the parasite.
Granuloma formation is the consequence of egg de-
position in the liver and is characterized by a gradual ac-
cumulation of neutrophils, eosinophils and mononuclear
cells. Tissue damage caused by profibrotic cells and
components [34] are targeted by vaccines that aim to re-
duce injury. Previous studies have characterized DNA-
Hsp65 as antifibrotic due to its ability to reduce tissue
damage in a model of induced granuloma in the lung
[28]. In that particular study, a static model with no
interference of the parasite was used, and the studies
were all performed in the lung 8 days post egg injection.
Here, we used a dynamic model of infection where the
effects of the vaccines were possibly modulated by im-
mune induction mediated by the worms during the
course of infection. Using different approaches, we were
able to observe the potential benefits of DNA-Hsp65 in
reducing chronic pathology in the liver of infected mice.
Figure 3 Combined DNA-Sm14/DNA-Hsp65 vaccination reduces
tissue damage during the chronic stages. A) Collagen area and
B) α-SMA area in liver granulomas of mice 69 days post infection
with S. mansoni in the presence or absence of immunization with
DNA-Sm14 or DNA-Sm14/DNA-Hsp65. Picrosirius staining was used
to measure collagen, and immunohistochemical staining was per-
formed to detect α-SMA. Quantitative analysis corresponding to the
area occupied by collagen and α-SMA fibers were determined by
digital densitometry recognition and expressed as a percentage of
the total area of each granuloma. The results are expressed as the
mean ± standard error of a total of 25 granulomas/group ***p < 0.001
vs Control group; #p < 0.01 vs DNA-Sm14. C) The concentration of
acid-soluble collagen per total protein measured in the supernatants of
the liver tissue homogenates. Soluble collagen was assayed using the
Sircol method, and total protein was measured using the Bradford
assay. The results are expressed as the mean ± standard error of 6-8
animals/group and are representative of two experiments *p < 0.05 vs
Control group 48 days; #p < 0.01 vs Control group 69 days.
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The antifibrotic role was observed by a reduction of
soluble and tissue collagen, α-SMA accumulation
around the granulomas 69 days post infection and
the maintenance of soluble collagen levels between
48 and 69 days post infection. These findings
confirm the immunostimulatory characteristics of
DNA-Hsp65, which are directly linked to a reduction
in chronic pathology and tissue damage during schis-
tosomiasis infection.
Conclusion
Simultaneous vaccination with DNA-Sm14/DNA-Hsp65
increased the number of CD8+ memory T cells and de-
creased egg viability on the intestinal wall of infected
mice. In addition, combined vaccination reduced colla-
gen and α-SMA accumulation during the chronic phase
of granuloma formation, indicating a potential antifibro-
tic property of DNA-Hsp65 that is associated with the
reduction of tissue damage (Figure 5).
Figure 4 DNA-Sm14/DNA-Hsp65 immunization reduced tissue damage during granuloma formation in the liver of Schistosoma
mansoni infected mice. Representative photomicrography of HE, Picrosirius and α-SMA staining from liver sections of mice without
immunization (Control), immunized with DNA-Sm14 or DNA-Sm14/DNa-Hsp65, 69 days after infection. HE and Picrosirius staining were used to
analyze granuloma formation and collagen deposition respectively. Immunohistochemical staining was performed to detect α-SMA fibers around
the granuloma. Original magnification, X50.
Figure 5 Protective effects of DNA-Sm14/DNA-Hsp65 immunization in mice infected with Schistosoma mansoni.
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Additional file
Additional file 1: Figure S1. Immunological profile of DNA-SM14/DNA-
Hsp65 did not overlap immune induction of DNA-Sm14. Table S1.
Anti-Sm14 IgG1/IgG2a ratio at different days after immunization with
DNA-Sm14 or DNA-Sm14/DNA-Hsp65. Figure S2. IFN-γ concentration
on bronchoalveolar lavage from mice immunized or not with DNA-Sm14,
DNA-Hsp65 or DNA-Sm14/DNA-Hsp65 and infected with S. mansoni.
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